98%
921
2 minutes
20
Cerebral pericytes are an integral component of the neurovascular unit, which governs the blood-brain barrier. There is paucity of knowledge on cortical pericytes across different dementias. We quantified cortical pericytes in capillaries in 124 post-mortem brains from subjects with post-stroke dementia (PSD), vascular dementia (VaD), Alzheimer's disease (AD) and AD-VaD (Mixed) and, post-stroke non-demented (PSND) stroke survivors as well as normal ageing controls. Collagen 4 (COL4)-positive nucleated pericyte soma were identified as protrusions on capillaries of the frontal cortex. The COL4-positive somata or nodule-like cell bodies were also verified by platelet derived growth factor receptor-β (PDGFR-β) immunohistochemistry. The mean (± SEM) pericyte somata in frontal cortical capillaries in normal young controls (46-65 years of age) was estimated as 5.2 ± 0.2 per mm capillary length. This number was reduced by 45% in older controls (> 78 years) to 2.9 ± 0.1 per mm capillary length (P < 0.001). We further found that the numbers of pericyte cell bodies per COL4 mm area or per mm capillary length were not decreased but rather preserved or increased in PSD, AD and Mixed dementia groups compared to similar age older controls (P < 0.01). Consistent with this, we noted that capillary length densities identified by the endothelial marker glucose transporter 1 or COL4 were not different across the dementias compared to older controls. There was a negative correlation with age (P < 0.001) suggesting fewer pericyte somata in older age, although the % COL4 immunoreactive capillary area was increased in older controls compared to young controls. Using a proven reliable method to quantify COL4-positive nucleated pericytes, our observations demonstrate ageing related loss but mostly preserved pericytes in the frontal cortex of vascular and AD dementias. We suggest there is differential regulation of capillary pericytes in the frontal lobe between the cortex and white matter in ageing-related dementias.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330023 | PMC |
http://dx.doi.org/10.1186/s40478-021-01230-6 | DOI Listing |
PLoS One
September 2025
Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Background: Stroke is a leading cause of death and disability globally, with frequent cognitive sequelae affecting up to 60% of stroke survivors. Despite the high prevalence of post-stroke cognitive impairment (PSCI), early detection remains underemphasized in clinical practice, with limited focus on broader neuropsychological and affective symptoms. Stroke elevates dementia risk and may act as a trigger for progressive neurodegenerative diseases.
View Article and Find Full Text PDFCNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFNumerous large-scale epidemiological studies investigating the trajectory of cognitive recovery after ischemic stroke have presented data suggesting an immediate drop in cognition acutely post-stroke followed by persistent, accelerated decline over time when averaged as a group. We sought to further examine this trend, speculating that the average persistent decline may be a reflection of two subgroups with vastly different prognoses: 1) a minority experiencing decline secondary to neurodegenerative processes like vascular dementia and Alzheimer's disease, and 2) a majority without marked progressive brain atrophy who typically see improvement. Our team thus investigated atrophy's association with language recovery, hypothesizing that declining naming performance in the year after left hemisphere ischemic stroke would be correlated to atrophy of the contralesional hemisphere.
View Article and Find Full Text PDFCureus
August 2025
Service of Neurology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRA.
Transcranial sonography (TCS) is widely acknowledged as a frontline imaging tool in movement disorder practice, particularly for separating idiopathic Parkinson's disease from its many mimics. In recent years, however, investigators have extended its reach, showing that the same portable probe can also capture structural and hemodynamic signatures of neuropsychiatric disorders and the major dementia syndromes. Across neuropsychiatry, a dim ("hypoechoic") median raphe emerges as the sonographic hallmark of serotonergic imbalance: it recurs in major depressive disorder, bipolar depression, and panic disorder, predicts better response to selective serotonin reuptake inhibitors, and even foreshadows post-stroke depression.
View Article and Find Full Text PDFFront Neurol
August 2025
Postdoctoral Innovation Practice Base of Hebei General Hospital, Shijiazhuang, China.
Objective: To identify significant predictors and construct a validated nomogram for predicting post-stroke cognitive impairment no dementia (PSCIND) risk among first-ever mild ischemic stroke (MIS) patients.
Methods: This retrospective cohort study analyzed 242 first-ever MIS patients categorized into normal cognitive ( = 137) and PSCIND ( = 105) groups. Comprehensive data encompassing demographic characteristics, laboratory parameters, cerebral small vessel disease (CSVD) imaging markers, neuropsychological assessments, and ischemic stroke lesion characteristics were collected.